These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 27913920)

  • 1. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    Ogawa E; Furusyo N; Nomura H; Dohmen K; Higashi N; Takahashi K; Kawano A; Azuma K; Satoh T; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J;
    J Gastroenterol; 2017 Jul; 52(7):845-854. PubMed ID: 27913920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tsuji K; Kurosaki M; Itakura J; Mori N; Takaki S; Hasebe C; Akahane T; Joko K; Yagisawa H; Takezawa J; Nakata R; Kusakabe A; Kojima Y; Kimura H; Tamada T; Kobashi H; Mitsuda A; Kondou M; Ogawa C; Uchida Y; Sohda T; Narita R; Izumi N
    J Gastroenterol; 2018 Oct; 53(10):1142-1150. PubMed ID: 29626296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
    Kozuka R; Hai H; Motoyama H; Hagihara A; Fujii H; Uchida-Kobayashi S; Morikawa H; Enomoto M; Murakami Y; Kawada N; Tamori A
    J Viral Hepat; 2018 May; 25(5):535-542. PubMed ID: 29274188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.
    Mawatari S; Oda K; Tabu K; Ijuin S; Kumagai K; Fujisaki K; Hashiguchi M; Inada Y; Uto H; Hiramine Y; Kure T; Hori T; Taniyama O; Kasai A; Tamai T; Moriuchi A; Ido A
    PLoS One; 2018; 13(6):e0198642. PubMed ID: 29856885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    Kan H; Imamura M; Kawakami Y; Daijo K; Teraoka Y; Honda F; Nakamura Y; Morio K; Kobayashi T; Nakahara T; Nagaoki Y; Kawaoka T; Tsuge M; Aikata H; Hayes CN; Miki D; Ochi H; Honda Y; Mori N; Takaki S; Tsuji K; Chayama K
    J Med Virol; 2017 Nov; 89(11):1963-1972. PubMed ID: 28657143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
    Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
    J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection.
    Lv DD; Wang ML; Chen EQ; Wu DB; Tao YC; Zhang DM; Tang H
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):382-388. PubMed ID: 30383554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM
    J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
    Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
    PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials.
    Tam E; Luetkemeyer AF; Mantry PS; Satapathy SK; Ghali P; Kang M; Haubrich R; Shen X; Ni L; Camus G; Copans A; Rossaro L; Guyer B; Brown RS;
    Liver Int; 2018 Jun; 38(6):1010-1021. PubMed ID: 29091342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2017 Jul; 89(7):1248-1254. PubMed ID: 28079269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
    Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
    Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of ledipasvir/sofosbuvir plus ribavirin for 12 weeks in patients with chronic hepatitis C genotype 3 and compensated liver disease.
    Moser S; Kozbial K; Laferl H; Schütz A; Reiberger T; Schwabl P; Gutic E; Schwanke C; Schubert R; Luhn J; Lang T; Schleicher M; Steindl-Munda P; Haltmayer H; Ferenci P; Gschwantler M
    Eur J Gastroenterol Hepatol; 2018 Mar; 30(3):291-295. PubMed ID: 29120906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
    Suda G; Ogawa K; Yamamoto Y; Katagiri M; Furuya K; Kumagai K; Konno J; Kimura M; Kawagishi N; Ohara M; Umemura M; Ito J; Izumi T; Nakai M; Sho T; Natsuizaka M; Morikawa K; Tsubota A; Shimada N; Iio E; Tanaka Y; Sakamoto N;
    J Gastroenterol; 2017 Oct; 52(10):1122-1129. PubMed ID: 28315983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
    Hsu SJ; Enkhzaya S; Lin YY; Tseng TC; Khosbayar T; Tsai CH; Wang TS; Enkhtuya D; Ivshinkhorol D; Naranzul N; Jargalsaikhan B; Amarsanaa J; Baatarkhuu O; Kao JH
    J Formos Med Assoc; 2020 Mar; 119(3):712-719. PubMed ID: 31672433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
    Hu C; Yuan G; Liu J; Huang H; Ren Y; Li Y; Chen X; Li W; Wu T; Deng H; Peng Y; Zhang YY; Zhou Y
    Can J Gastroenterol Hepatol; 2018; 2018():3908767. PubMed ID: 30538973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.